Advanced search

Vol 62, No 1 (2024)
Original paper
Published online: 2024-04-04

open access

View PDF Download PDF file
Page views 592
Article views/downloads 271
Get Citation

Connect on Social Media

Connect on Social Media

Effects of bone marrow mesenchymal stem cell-conditioned medium on the proliferation and migration of liposarcoma cells

Hua Chen1, Na Sha1, Ning Liu1, Haijun Hu2
DOI: 10.5603/fhc.98379
Pubmed: 38639334
Folia Histochem Cytobiol 2024;62(1):50-60.

Abstract

Introduction. Liposarcoma constitutes a prevalent subtype of soft tissue sarcoma, represents approximately 20% of all sarcomas. However, conventional chemotherapeutic agents have shown restricted effectiveness in treating liposarcoma patients. Accumulating evidence indicates that mesenchymal stem cells (MSCs) have the characteristic of migration to tumor site, promote or suppress tumors. How human bone marrow mesenchymal stem cells (BMSCs) contribute to liposarcoma phenotype remains poorly understood. This study aims to investigate the effects of human bone marrow mesenchymal stem cell-conditioned medium (BMSC-CM) on the proliferation and migration of liposarcoma cell lines 93T449 and SW872, as well as explore potential underlying mechanisms of BMSC-CM action on these cells.

Materials and methods. We transfected BMSCs with lentiviral constructs to knock down the transcriptional co-activator Yes-associated protein 1 (YAP1), conditioned medium (CM) obtained from BMSCs and shYAP1-BMSC, respectively. Liposarcoma cell lines 93T449 and SW872 were co-cultured with BMSC-CM or shYAP1-BMSC-CM. Cell proliferation ability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell apoptosis was evaluated using flow cytometric assay. A wound healing assay was used to analyze cell migration. The expression levels of YAP1, Bcl-2, and matrix metalloproteinase-2 (MMP-2) were determined by western blot assay.

Results. Co-culturing liposarcoma cell lines 93T449 and SW872 with BMSC-CM promoted tumor cell proliferation, while shYAP1-BMSC-CM significantly inhibited cell viability and migration, induced apoptosis, and downregulated Bcl-2 and MMP-2 expression.

Conclusions. These findings provide new insights into the impact of BMSC-CM on liposarcoma and suggest its possible involvement in liposarcoma cell growth.

Keywords: human BMSCconditioned mediumliposarcomaproliferationmigrationYAP1 silencing

Article available in PDF format

View PDF Download PDF file

References

  1. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica. 2021; 113(2): 70–84.
    CrossRefPubMed
  2. Schöffski P. Established and experimental systemic treatment options for advanced liposarcoma. Oncol Res Treat. 2022; 45(9): 525–543.
    CrossRefPubMed
  3. Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020; 21(10): 1366–1377.
    CrossRefPubMed
  4. Callegaro D, Raut CP, Ajayi T, et al. Preoperative radiotherapy in patients with primary retroperitoneal sarcoma: EORTC-62092 trial (STRASS) versus off-trial (STREXIT) results. Ann Surg. 2023; 278(1): 127–134.
    CrossRefPubMed
  5. Erstad DJ, Chiang YJ, Witt RG, et al. Clinical impact of external beam radiotherapy for surgically resected primary retroperitoneal liposarcoma. Ann Surg Oncol. 2023; 30(2): 926–940.
    CrossRefPubMed
  6. von Mehren M, Kane JM, Agulnik M, et al. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(7): 815–833.
    CrossRefPubMed
  7. Stacchiotti S, Van der Graaf WTA, Sanfilippo RG, et al. First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. Cancer. 2022; 128(15): 2932–2938.
    CrossRefPubMed
  8. Schöffski P, Grignani G, Blay JY, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016; 387(10028): 1629–1637.
    CrossRefPubMed
  9. Patel S, von Mehren M, Reed DR, et al. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2019; 125(15): 2610–2620.
    CrossRefPubMed
  10. Gleason CE, Dickson MA, Klein Dooley ME, et al. Therapy-induced senescence contributes to the efficacy of abemaciclib in patients with dedifferentiated liposarcoma. Clin Cancer Res. 2024; 30(4): 703–718.
    CrossRefPubMed
  11. Abdul Razak AR, Bauer S, Suarez C, et al. Co-Targeting of MDM2 and CDK4/6 with siremadlin and ribociclib for the treatment of patients with well-differentiated or dedifferentiated liposarcoma: results from a proof-of-concept, phase ib study. Clin Cancer Res. 2022; 28(6): 1087–1097.
    CrossRefPubMed
  12. Kyriazoglou A, Gkaralea LE, Kotsantis I, et al. Tyrosine kinase inhibitors in sarcoma treatment. Oncol Lett. 2022; 23(6): 183.
    CrossRefPubMed
  13. Blay JY, Chevret S, Le Cesne A, et al. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial. Lancet Oncol. 2023; 24(8): 892–902.
    CrossRefPubMed
  14. Gounder MM, Razak AA, Somaiah N, et al. Selinexor in advanced, metastatic dedifferentiated liposarcoma: a multinational, randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2022; 40(22): 2479–2490.
    CrossRefPubMed
  15. Li X, Fan Q, Peng X, et al. Mesenchymal/stromal stem cells: necessary factors in tumour progression. Cell Death Discov. 2022; 8(1): 333.
    CrossRefPubMed
  16. Slama Y, Ah-Pine F, Khettab M, et al. The dual role of mesenchymal stem cells in cancer pathophysiology: pro-tumorigenic effects versus therapeutic potential. Int J Mol Sci. 2023; 24(17).
    CrossRefPubMed
  17. Rodriguez R, Tornin J, Suarez C, et al. Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation. Stem Cells. 2013; 31(10): 2061–2072.
    CrossRefPubMed
  18. Kim YuJ, Kim M, Park HK, et al. Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology. Lab Invest. 2019; 99(9): 1309–1320.
    CrossRefPubMed
  19. Jo EB, Lee H, Lee KW, et al. Complete regression of metastatic de-differentiated liposarcoma with engineered mesenchymal stromal cells with dTRAIL and HSV-TK. Am J Transl Res. 2020; 12(7): 3993–4000.
    PubMed
  20. Pocaterra A, Romani P, Dupont S. YAP/TAZ functions and their regulation at a glance. J Cell Sci. 2020; 133(2).
    CrossRefPubMed
  21. Piccolo S, Panciera T, Contessotto P, et al. YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. Nat Cancer. 2023; 4(1): 9–26.
    CrossRefPubMed
  22. Trautmann M, Cheng YY, Jensen P, et al. Requirement for YAP1 signaling in myxoid liposarcoma. EMBO Mol Med. 2019; 11(5).
    CrossRefPubMed
  23. Morice S, Mullard M, Brion R, et al. The YAP/TEAD axis as a new therapeutic target in osteosarcoma: effect of verteporfin and CA3 on primary tumor growth. Cancers (Basel). 2020; 12(12).
    CrossRefPubMed
  24. Gao R, Kalathur RKR, Coto-Llerena M, et al. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med. 2021; 13(12): e14351.
    CrossRefPubMed
  25. Lo Sardo F, Pulito C, Sacconi A, et al. YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer. Cancer Lett. 2021; 500: 51–63.
    CrossRefPubMed
  26. Salem O, Hansen CG. The hippo pathway in prostate cancer. Cells. 2019; 8(4).
    CrossRefPubMed
  27. Rybarczyk A, Klacz J, Wronska A, et al. Overexpression of the YAP1 oncogene in clear cell renal cell carcinoma is associated with poor outcome. Oncol Rep. 2017; 38(1): 427–439.
    CrossRefPubMed
  28. Cha YJ, Bae SJ, Kim D, et al. High nuclear expression of yes-associated protein 1 correlates with metastasis in patients with breast cancer. Front Oncol. 2021; 11: 609743.
    CrossRefPubMed
  29. Cymbaluk-Płoska A, Chudecka K, Chudecka-Głaz A, et al. Importance of Potential New Biomarkers in Patient with Serouse Ovarian Cancer. Diagnostics (Basel). 2021; 11(6).
    CrossRefPubMed
  30. Zhou X, Yan Z, Hou J, et al. The Hippo-YAP signaling pathway drives CD24-mediated immune evasion in esophageal squamous cell carcinoma via macrophage phagocytosis. Oncogene. 2024; 43(7): 495–510.
    CrossRefPubMed
  31. Ono S, Nakano K, Takabatake K, et al. Immunohistochemistry of YAP and dNp63 and survival analysis of patients bearing precancerous lesion and oral squamous cell carcinoma. Int J Med Sci. 2019; 16(5): 766–773.
    CrossRefPubMed
  32. Cheung P, Xiol J, Dill MT, et al. Regenerative reprogramming of the intestinal stem cell state via hippo signaling suppresses metastatic colorectal cancer. Cell Stem Cell. 2020; 27(4): 590–604.e9.
    CrossRefPubMed
  33. Yuan M, Tomlinson V, Lara R, et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ. 2008; 15(11): 1752–1759.
    CrossRefPubMed
  34. Li Xu, Zhuo S, Zhuang T, et al. YAP inhibits ERα and ER breast cancer growth by disrupting a TEAD-ERα signaling axis. Nat Commun. 2022; 13(1): 3075.
    CrossRefPubMed
  35. Li Xu, Zhuo S, Cho YS, et al. YAP antagonizes TEAD-mediated AR signaling and prostate cancer growth. EMBO J. 2023; 42(4): e112184.
    CrossRefPubMed
  36. Huang H, Zhang W, Pan Y, et al. YAP suppresses lung squamous cell carcinoma progression via deregulation of the dnp63-gpx2 axis and ROS accumulation. Cancer Res. 2017; 77(21): 5769–5781.
    CrossRefPubMed
  37. Frost TC, Gartin AK, Liu M, et al. YAP1 and WWTR1 expression inversely correlates with neuroendocrine markers in Merkel cell carcinoma. J Clin Invest. 2023; 133(5).
    CrossRefPubMed
  38. Cottini F, Hideshima T, Xu C, et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med. 2014; 20(6): 599–606.
    CrossRefPubMed
  39. Maruyama J, Inami K, Michishita F, et al. Novel YAP1 activator, identified by transcription-based functional screen, limits multiple myeloma growth. Mol Cancer Res. 2018; 16(2): 197–211.
    CrossRefPubMed
  40. Mokhtari RB, Ashayeri N, Baghaie L, et al. The hippo pathway effectors YAP/TAZ-TEAD oncoproteins as emerging therapeutic targets in the tumor microenvironment. Cancers (Basel). 2023; 15(13).
    CrossRefPubMed
  41. Mi F, Gong L. Secretion of interleukin-6 by bone marrow mesenchymal stem cells promotes metastasis in hepatocellular carcinoma. Biosci Rep. 2017; 37(4).
    CrossRefPubMed
  42. Meng L, Zhao Y, Bu W, et al. Bone mesenchymal stem cells are recruited via CXCL8-CXCR2 and promote EMT through TGF-β signal pathways in oral squamous carcinoma. Cell Prolif. 2020; 53(8): e12859.
    CrossRefPubMed
  43. Pietrovito L, Leo A, Gori V, et al. Bone marrow-derived mesenchymal stem cells promote invasiveness and transendothelial migration of osteosarcoma cells via a mesenchymal to amoeboid transition. Mol Oncol. 2018; 12(5): 659–676.
    CrossRefPubMed
  44. Huang J, Wang X, Wen J, et al. Gastric cancer cell-originated small extracellular vesicle induces metabolic reprogramming of BM-MSCs through ERK-PPARγ-CPT1A signaling to potentiate lymphatic metastasis. Cancer Cell Int. 2023; 23(1): 87.
    CrossRefPubMed
  45. Cai X, Wang KC, Meng Z. Mechanoregulation of YAP and TAZ in Cellular Homeostasis and Disease Progression. Front Cell Dev Biol. 2021; 9: 673599.
    CrossRefPubMed
  46. Totaro A, Panciera T, Piccolo S. YAP/TAZ upstream signals and downstream responses. Nat Cell Biol. 2018; 20(8): 888–899.
    CrossRefPubMed
  47. Stampouloglou E, Cheng N, Federico A, et al. Yap suppresses T-cell function and infiltration in the tumor microenvironment. PLoS Biol. 2020; 18(1): e3000591.
    CrossRefPubMed
  48. Yamaguchi H, Taouk GM. A potential role of YAP/TAZ in the interplay between metastasis and metabolic alterations. Front Oncol. 2020; 10: 928.
    CrossRefPubMed
  49. Wang M, Zhao X, Qiu R, et al. Lymph node metastasis-derived gastric cancer cells educate bone marrow-derived mesenchymal stem cells via YAP signaling activation by exosomal Wnt5a. Oncogene. 2021; 40(12): 2296–2308.
    CrossRefPubMed
  50. Yoshida M, Horiguchi H, Kikuchi S, et al. miR-7977 inhibits the Hippo-YAP signaling pathway in bone marrow mesenchymal stromal cells. PLoS One. 2019; 14(3): e0213220.
    CrossRefPubMed
  51. Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019; 20(3): 175–193.
    CrossRefPubMed
  52. Qian S, Wei Z, Yang W, et al. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022; 12: 985363.
    CrossRefPubMed
  53. Muenchow A, Weller S, Hinterleitner C, et al. The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA. Cell Death Dis. 2020; 11(8): 701.
    CrossRefPubMed
  54. Liao ZB, Tan XL, Dong KS, et al. miRNA-448 inhibits cell growth by targeting BCL-2 in hepatocellular carcinoma. Dig Liver Dis. 2019; 51(5): 703–711.
    CrossRefPubMed
  55. Kaban K, Hinterleitner C, Zhou Y, et al. Therapeutic silencing of BCL-2 using NK cell-derived exosomes as a novel therapeutic approach in breast cancer. Cancers (Basel). 2021; 13(10).
    CrossRefPubMed
  56. Di Martile M, Farini V, Consonni FM, et al. Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages. J Immunother Cancer. 2020; 8(1).
    CrossRefPubMed
  57. Song S, Chen Q, Li Y, et al. Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. Gut. 2021; 70(12): 2238–2248.
    CrossRefPubMed
  58. Henriet P, Emonard H. Matrix metalloproteinase-2: Not (just) a "hero" of the past. Biochimie. 2019; 166: 223–232.
    CrossRefPubMed
  59. Gonzalez-Avila G, Sommer B, Mendoza-Posada DA, et al. Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer. Crit Rev Oncol Hematol. 2019; 137: 57–83.
    CrossRefPubMed
  60. Ratajczak-Wielgomas K, Kmiecik A, Dziegiel P. Role of periostin expression in non-small cell lung cancer: periostin silencing inhibits the migration and invasion of lung cancer cells via regulation of MMP-2 expression. Int J Mol Sci. 2022; 23(3).
    CrossRefPubMed
  61. Zhao H, Xing F, Yuan J, et al. Sevoflurane inhibits migration and invasion of glioma cells via regulating miR-34a-5p/MMP-2 axis. Life Sci. 2020; 256: 117897.
    CrossRefPubMed
  62. Gu Ye, Yu J, Ding C, et al. Flavonoid GL-V9 suppresses invasion and migration of human colorectal cancer cells by inhibiting PI3K/Akt and MMP-2/9 signaling. J Cancer. 2021; 12(15): 4542–4551.
    CrossRefPubMed
  63. Huang CC, Wang PH, Lu YT, et al. Morusin Suppresses Cancer Cell Invasion and MMP-2 Expression through ERK Signaling in Human Nasopharyngeal Carcinoma. Molecules. 2020; 25(20).
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note